| P2093 | author name string | J P Eder | |
| | D B Doroshow | |
| | P M LoRusso | |
| P2860 | cites work | Translating the Histone Code | Q22065840 |
| | Selective inhibition of BET bromodomains | Q24301009 |
| | Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression | Q24301464 |
| | The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription | Q24316236 |
| | The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription | Q24319771 |
| | An operational definition of epigenetics | Q24568002 |
| | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) | Q24681480 |
| | Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways | Q24681762 |
| | Suppression of inflammation by a synthetic histone mimic | Q27665789 |
| | Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Q27674674 |
| | Chromatin modifications and their function | Q27861067 |
| | Targeting bromodomains: epigenetic readers of lysine acetylation | Q28238635 |
| | The mechanisms behind the therapeutic activity of BET bromodomain inhibition | Q28241504 |
| | BET bromodomain inhibition as a therapeutic strategy to target c-Myc | Q28247024 |
| | Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4 | Q28267929 |
| | BET domain co-regulators in obesity, inflammation and cancer | Q28269301 |
| | Two faces of brd4: mitotic bookmark and transcriptional lynchpin | Q28278777 |
| | Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study | Q28301602 |
| | Perceptions of epigenetics | Q29547310 |
| | Epigenetics in cancer | Q29547853 |
| | Cancer epigenomics: DNA methylomes and histone-modification maps | Q29615524 |
| | Anticancer activities of histone deacetylase inhibitors | Q29616624 |
| | Targeting MYC dependence in cancer by inhibiting BET bromodomains | Q29617196 |
| | RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia | Q29617201 |
| | The history of cancer epigenetics | Q29617273 |
| | Selective inhibition of tumor oncogenes by disruption of super-enhancers | Q29617301 |
| | The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis | Q29618035 |
| | Overcoming Resistance to Targeted Therapies in Cancer | Q38651717 |
| | Epigenetics: A primer for clinicians | Q38770916 |
| | BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma | Q38771627 |
| | BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells | Q38799987 |
| | Mechanisms of tumor cell resistance to the current targeted-therapy agents. | Q38828353 |
| | Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue | Q38850598 |
| | The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. | Q38916281 |
| | Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. | Q39033630 |
| | Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer | Q39051416 |
| | The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. | Q42699806 |
| | Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. | Q42707919 |
| | Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements | Q46597773 |
| | Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition | Q49092875 |
| | Master transcription factors and mediator establish super-enhancers at key cell identity genes | Q29618062 |
| | Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma | Q33375600 |
| | Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628 | Q33430717 |
| | Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study | Q33431391 |
| | Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. | Q33601156 |
| | Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines | Q33659363 |
| | BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma | Q33853887 |
| | An epigenomic approach to therapy for tamoxifen-resistant breast cancer | Q33859350 |
| | Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study | Q34046624 |
| | BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin | Q34046783 |
| | BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. | Q34047394 |
| | Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. | Q34128471 |
| | PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains | Q34338531 |
| | Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer | Q34416771 |
| | The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors | Q34541532 |
| | BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy | Q34626550 |
| | Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription | Q35007045 |
| | The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. | Q35096586 |
| | Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. | Q35801267 |
| | Concomitant BET and MAPK blockade for effective treatment of ovarian cancer | Q35843618 |
| | Clinical progress and pharmacology of small molecule bromodomain inhibitors. | Q36050595 |
| | BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells | Q36232141 |
| | Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling | Q36356381 |
| | Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells | Q36545233 |
| | The Myc oncoprotein as a therapeutic target for human cancer | Q36578165 |
| | The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase | Q36727254 |
| | Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma | Q36776382 |
| | Targeting MYCN in neuroblastoma by BET bromodomain inhibition | Q36903802 |
| | Epigenetic changes in cancer | Q37288845 |
| | Reflecting on 25 years with MYC. | Q37333643 |
| | Regulation of aurora B expression by the bromodomain protein Brd4. | Q37334019 |
| | BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. | Q37420196 |
| | Targeting the histone orthography of cancer: drugs for writers, erasers and readers | Q38231327 |
| | Histone deacetylase inhibitors in hematological malignancies and solid tumors | Q38344675 |
| P433 | issue | 8 | |
| P304 | page(s) | 1776-1787 | |
| P577 | publication date | 2017-08-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | BET inhibitors: a novel epigenetic approach | |
| P478 | volume | 28 | |